The CREDENCE (Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants with Diabetic Nephropathy) trial [5] and DAPA-CKD (Dapagliflozin in Patients with Chronic Kidney Disease) trial [6]—both dedicated renal outcome trials involving the SGLT2 inhibitor class—reported that both canagliflozin and dapagliflozin significantly reduced the composite of a sustained eGFR decline ≥ 50%, end-stage kidney disease or death from renal or cardiovascular causes. This evidence concerns the gene SLC5A2 and chronic kidney disease.